In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Repligen Corp.

http://www.repligen.com

Latest From Repligen Corp.

Deal Watch: Sanofi To Tap Owkin’s AI, Machine Learning In Oncology

French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.

Deal Watch Business Strategies

Dealmaking Quarterly Statistics, Q3 2021

In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.

Deals Financing

Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total

Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.

Financing Innovation

BeiGene’s Brukinsa Among Nine Drugs To Win EU Marketing Thumbs Up

A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval. 

Europe Approvals
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Atoll GmBH
    • C Technologies, Inc.
    • Novozymes Biopharma Sweden AB
    • TangenX Technology Corporation
    • Polymem S.A.
UsernamePublicRestriction

Register